Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andexanet Reversal of Betrixaban Anticoagulation in Healthy Subjects
NCT03330457Phase 2Terminated
- Sponsor
- Portola Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of andexanet alfa in hemorrhage, sponsored by Portola Pharmaceuticals. Started Aug 2015; status: terminated.
02
Drugs
andexanet alfa
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT03330457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330457.